Breast Carcinoma

Trastuzumab emtansine has its indication for patients with HER2-positive metastatic breast cancer after therapy with Trastuzumab and Taxane, approval based on PFS and preliminary OS data. EMILIA was a… (full text at CIViC)

PMID 28526536 · Diéras et al., 2017 · Open in CIViC

In a cohort of 205 Her2-receptor amplified breast cancers, 20 experienced recurrence after trastuzumab therapy. Of the 20 recurrent cases, only six patients had metastatic sites, excluding brain metas… (full text at CIViC)

PMID 27900589 · Hirotsu et al., 2017 · Open in CIViC

In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored higher than median levels of ERBB3 mRNA treated with ado-trastuzumab emtansine (T-DM1… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

Preventing HER4 cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response… (full text at CIViC)

PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC

siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.

PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC

In the concurrently randomized cohort of the same phase 3 trial in ER-positive, HER2-negative breast carcinoma (NCT04975308; n = 426, 213 per arm), imlunestrant plus abemaciclib improved investigator-… (full text at CIViC)

PMID 39660834 · Jhaveri et al., 2025 · Open in CIViC

In a randomized, open-label phase 3 trial in ER-positive, HER2-negative breast carcinoma (EMBER-3, NCT04975308; n = 874; ESR1-mut subgroup n = 256), imlunestrant monotherapy (n=331) improved investiga… (full text at CIViC)

PMID 39660834 · Jhaveri et al., 2025 · Open in CIViC

In a multicenter open label phase 1 to 2 trial in locally advanced or metastatic ER positive, HER2 negative breast carcinoma (NCT03250676; n = 151; RP2D cohort 450 mg once daily n = 115, response eval… (full text at CIViC)

PMID 40830892 · Hamilton et al., 2025 · Open in CIViC

A 6-year-old female had invasive breast adenocarcinoma with the histopathologic features of a secretory breast carcinoma (SBC). FISH and RT-PCR on frozen tumor tissue found ETV6::NTRK3 fusion. 11 of … (full text at CIViC)

PMID 12450792 · Tognon et al., 2002 · Open in CIViC

In developing a FISH assay to detect ETV6::NTRK3 fusions, the authors found 3 of 4 secretary breast carcinomas were positive for the fusion. In a subsequent analysis of an invasive breast carcinoma t… (full text at CIViC)

PMID 15101049 · Makretsov et al., 2004 · Open in CIViC

1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between tr… (full text at CIViC)

PMID 24989892 · Norton et al., 2014 · Open in CIViC

1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistically significant difference in disease-free survi… (full text at CIViC)

PMID 24989892 · Norton et al., 2014 · Open in CIViC

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC

ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… (full text at CIViC)

PMID 24124571 · Li et al., 2013 · Open in CIViC

This study showed that the carriers of the T allele had a significantly less favourable course of the disease when compared to carriers of the homozygous CC genotype. GNAS 393C homozygous patients of … (full text at CIViC)

PMID 17186357 · Otterbach et al., 2007 · Open in CIViC

MMP2 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Hig… (full text at CIViC)

PMID 26921265 · Tabouret et al., 2016 · Open in CIViC

MMP9 serum levels were assessed (ELISA) at baseline (b) and before surgery in 45 available samples from patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant therapy. Low… (full text at CIViC)

PMID 26921265 · Tabouret et al., 2016 · Open in CIViC

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PI… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirall… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

This preclinical study tested the efficacy on several HER2 amplified breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases at a range of … (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

As part of a pre-clinical experiment, the efficacy of trastuzumab was evaluated against various HER2 positive cell lines. EFM-192A cell line expressing PIK3CA C420R was associated with resistance to t… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

As part of a preclinical study, the efficacy of PI-103 (a dual inhibitor of MTOR and Class IA PI3Ks) was evaluated for several cell lines of breast cancer. Sensitivity and resistance was categorized a… (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

As part of a preclinical study, the efficacy of PI3KA/Di—a selective inhibitor for the α and δ subunits of class I PI3K—was evaluated for several cell lines of breast cancer. Sensitivity and resistanc… (full text at CIViC)

PMID 20453058 · O'Brien et al., 2010 · Open in CIViC

This preclinical study tested the sensitivity of HER2-positive breast cancer cell line BT-474 (heterozygous for PIK3CA K111N) retrovirally transduced with PIK3CA E545K to NVP-BEZ235 (dactolisib; a dua… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

In a preclinical study, efficacy of trastuzumab and NVP-BEZ235 (dactolisib) combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PI… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

The HER2 breast cancer cell line KPL4 with PIK3CA H1047R shows sub-optimal responses to trastuzumab and lapatinib, and was used to establish mouse xenografts. Treatment of mice with monotherapy of AZD… (full text at CIViC)

PMID 22294718 · Davies et al., 2012 · Open in CIViC

Tumor xenografts in mice were established with the KPL4 HER2 positive breast cancer cell line with PIK3CA H1047R mutation. KPL4 has suboptimal responses to trastuzumab and lapatinib. Xengraft treatmen… (full text at CIViC)

PMID 22294718 · Davies et al., 2012 · Open in CIViC